Alexion Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alexion Pharmaceuticals, Inc. (ALXN), a biopharmaceutical company founded in 1992 and headquartered in Boston, Massachusetts, develops and commercializes innovative therapies for patients with rare diseases through its complement biology platform and enzyme replacement technologies; its marketed products include Soliris (eculizumab) and Ultomiris (ravulizumab), long-acting C5 complement inhibitors for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder; Strensiq (asfotase alfa) for hypophosphatasia; Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency; Koselugo (selumetinib), a kinase inhibitor; and Andexxa (andexanet alfa), a Factor Xa inhibitor reversal agent. The company operates globally across hematology, nephrology, neurology, metabolics, cardiology, and emerging areas such as ophthalmology and bone metabolism, serving patients and healthcare providers in major markets including the United States, Europe, Japan, and other regions through its integration as Alexion, AstraZeneca Rare Disease. Alexion maintains a robust pipeline of over 15 investigational therapies, including Ultomiris expansions into immunoglobulin A nephropathy, lupus nephritis, and hematopoietic stem cell transplant-associated thrombotic microangiopathy; next-generation enzyme replacements like efzimfotase alfa (ALXN1850) and ALXN1910 for hypophosphatasia; oral factor D inhibitors danicopan and vemircopan; gefurulimab for generalized myasthenia gravis; and ALXN2220, under exclusive global license with Neurimmune AG for transthyretin amyloid cardiomyopathy. Following its acquisition by AstraZeneca in 2021 for $39 billion, Alexion leverages AstraZeneca's global infrastructure for expanded commercialization and pipeline acceleration, including an exclusive worldwide license agreement in 2024 with Monopar Therapeutics for ALXN-1840 (bis-choline tetrathiomolybdate) in Wilson disease; however, AstraZeneca discontinued two Alexion rare disease assets in early 2025 due to efficacy shortfalls.
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
5 Biotech Acquisition Targets To Accumulate In 2024
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology
AstraZeneca and Alexion working with FDA on US label expansion for Ultomiris
BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases
JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
AstraZeneca to pay US$775mln to settle Alexion patent dispute
AstraZeneca PLC boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinet
AstraZeneca's takeover of Alexion the highlight of a quieter quarter for mergers & acquisitions
Jeremy Grantham's Firm Profits From Wave of Acquisitions in 3rd Quarter